IMVT vs PSX · $2.90B cap vs P/E 17, rev $83.54B
Immunovant Inc (IMVT) versus Phillips 66 (PSX) — a side-by-side from cached financials, not a winner call.
Immunovant Inc (IMVT) is a biotechnology company listed on US.
Phillips 66 (PSX) is a oil & gas refining & marketing company listed on NYSE.
IMVT does not have a complete income-statement cache yet.
Latest reported PSX revenue for 2026-06-30 was $83.54B. Net income was $4.05B. PSX currently screens at market cap $67.02B and trailing P/E 16.5.
IMVT currently screens at market cap $2.90B. PSX currently screens at market cap $67.02B and trailing P/E 16.5.
Not investment advice. Open the IMVT and PSX stock pages for the full models.
Not investment advice.